General
Preferred name
BETAHISTINE
Synonyms
BETAHISTINE HYDROCHLORIDE ()
N-methyl-2-pyridin-2-ylethanamine ()
Vasomotal ()
Serc base ()
PT 9 base ()
Betahistine 2HCl ()
PT-9 ()
Betahistine dihydrochloride ()
Extovyl ()
Meginalisk ()
Melopat ()
Betahistine mesylate ()
N-methyl-2-(pyridin-2-yl)ethanamine ()
Betahistine (dihydrochloride) ()
Betahistine (mesylate) ()
betahistine, Labopharm ()
Serc ()
Betahistine hcl ()
Serc-8 ()
Serc-16 ()
NSC-757397 ()
Betahistine (hydrochloride) ()
Betahistine-d3 (hydrochloride) ()
P&D ID
PD009287
CAS
5579-84-0
5638-76-6
133206-34-5
54856-23-4
244094-72-2
Tags
natural product
drug
available
Drug Status
investigational
approved
withdrawn
Drug indication
Vasodilator
Discovery agent
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS
Betahistine primarily acts as a histamine H1-agonist with 0.07 times the activity of histamine. Stimulating the H1-receptors in the inner ear causes a vasodilatory effect and increased permeability in the blood vessels which results in reduced endolymphatic pressure. Betahistine is believed to act by reducing the asymmetrical functioning of sensory vestibular organs as well as by increasing vestibulocochlear blood flow. Doing so aids in decreasing symptoms of vertigo and balance disorders.; Betahistine also acts as a histamine H3-receptor antagonist which causes an increased output of histamine from histaminergic nerve endings which can further increase the direct H1-agonist activity. Furthermore, H3-receptor antagonism increases the levels of neurotransmitters such as serotonin in the brainstem, which inhibits the activity of vestibular nuclei, helping to restore proper balance and decrease in vertigo symptoms.
DESCRIPTION
This is an orally delivered histamine receptor modulator that has weak agonist activity at histamine H1 receptors and more potent antagonist activity at the H3 receptor subtype .
(GtoPdb)
DESCRIPTION
Betahistine is a structural analog of histamine that acts as a weak partial postsynaptic histamine H1 receptor agonist and presynaptic H3 receptor antagonist, with no effect on postsynaptic H2 receptors. Betahistine, sold under the brand name Serc among others, is an anti-vertigo medication. It is commonly prescribed for balance disorders or to alleviate vertigo symptoms, e.g. those associated with Ménière's disease.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Betahistine is a histamine H3 receptors inhibitor with IC50 of 1.9 μM.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
21
BOC Sciences Bioactive Compounds
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
64
Molecular Weight
136.1
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
3
Ring Count
1
Aromatic Ring Count
1
cLogP
0.84
TPSA
24.92
Fraction CSP3
0.38
Chiral centers
0.0
Largest ring
6.0
QED
0.67
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Immunology/Inflammation
Neuroscience
Neuronal Signaling
Target
H1 receptor
H3 receptor
HRH1, HRH3
Histamine Receptor
Member status
member
MOA
Histamine H3 Receptor Antagonists
Histamine H1 Receptor Agonists
histamine receptor agonist, histamine receptor antagonist
Indication
Meniere's disease
Solubility
DMSO (Slightly), Methanol (Slightly), Water (Slightly)
Source data
